Sotagliflozin: a dual sodium-glucose co-transporter-1 and -2 inhibitor for the management of Type 1 and Type 2 diabetes mellitus

Diabetic Medicine

Volumn 35, Issue 8, 2018, Pages 1037-1048

  Sims, H ^a   Smith, K H ^a   Bramlage, P ^b   Minguet, J ^a  

^a Institute for Research and Medicine Advancement (IRMEDICA)   (Spain)

^b Institute for Pharmacology and Preventative Medicine   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

SOTAGLIFLOZIN; (2S,3R,4R,5S,6R)-2-(4-CHLORO-3-(4-ETHOXYBENZYL)PHENYL)-6-(METHYLTHIO)TETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; ANTIDIABETIC AGENT; GLYCOSIDE; SLC5A1 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 1;

AMPUTATION; DIABETIC KETOACIDOSIS; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG LEGISLATION; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY INJURY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARMACEUTICAL CARE; PHARMACODYNAMICS; PHARMACOKINETIC PARAMETERS; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; UROGENITAL TRACT INFECTION; ANTAGONISTS AND INHIBITORS; BLOOD; DRUG EFFECT; GLUCOSE BLOOD LEVEL; METABOLISM;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; GLYCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; SODIUM-GLUCOSE TRANSPORTER 1; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS;

EID: 85050110454     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.13645     Document Type: Review

References (66)

1. Wright EM, Hirayama BA, Loo DF. Active sugar transport in health and disease. J Intern Med 2007; 261: 32–43.
2. Poulsen SB, Fenton RA, Rieg T. Sodium-glucose cotransport. Curr Opin Nephrol Hypertens 2015; 24: 463–469.
3. Chen J, Williams S, Ho S, Loraine H, Hagan D, Whaley JM et al. Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members. Diabetes Ther 2010; 1: 57–92.
4. Lu Y, Griffen SC, Boulton DW, Leil TA. Use of systems pharmacology modeling to elucidate the operating characteristics of SGLT1 and SGLT2 in renal glucose reabsorption in humans. Frontiers Pharmacol 2014; 5: 274.
5. Dyer J, Wood IS, Palejwala A, Ellis A, Shirazi-Beechey SP. Expression of monosaccharide transporters in intestine of diabetic humans. Am J Physiol Gastrointest Liver Physiol 2002; 282: G241–248.
6. Rahmoune H, Thompson PW, Ward JM, Smith CD, Hong G, Brown J. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 2005; 54: 3427–3434.
7. Burant CF, Flink S, DePaoli AM, Chen J, Lee WS, Hediger MA et al. Small intestine hexose transport in experimental diabetes. Increased transporter mRNA and protein expression in enterocytes. J Clin Invest 1994; 93: 578–585.
8. Wright EM, Loo DD, Hirayama BA. Biology of human sodium glucose transporters. Physiol Rev 2011; 91: 733–794.
9. Musso G, Gambino R, Cassader M, Pagano G. A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials. Ann Med 2012; 44: 375–393.
10. Komoroski B, Vachharajani N, Feng Y, Li L, Kornhauser D, Pfister M. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther 2009; 85: 513–519.
11. Sha S, Devineni D, Ghosh A, Polidori D, Chien S, Wexler D et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab 2011; 13: 669–672.
12. Liu J, Lee T, DeFronzo RA. Why Do SGLT2 Inhibitors Inhibit Only 30–50% of Renal Glucose Reabsorption in Humans? Diabetes 2012; 61: 2199–2204.
13. De Silva A, Bloom SR. Gut Hormones and Appetite Control: A Focus on PYY and GLP-1 as Therapeutic Targets in Obesity. Gut Liver 2012; 6: 10–20.
14. Majewski C, Bakris GL. Blood Pressure Reduction: An Added Benefit of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes. Diabetes Care 2015; 38: 429–430.
15. Garg SK, Henry RR, Banks P, Buse JB, Davies MJ, Fulcher GR et al. Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes. N Engl J Med 2017; 377: 2337–2348.
16. Danne T, Cariou B, Banks P, Sawhney S, Strumph P. 146-LB — 2017: 24-Week Efficacy and Safety of Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes (inTandem2). ADA 77th Scientific Sessions; 11th June; San Diego, CA: American Diabetes Association, 2017.
17. Buse JB, Garg SK, Rosenstock J, Banks P, Sawhney S, Strumph P. 69-OR - Twenty-Four-Week Efficacy and Safety of Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes (inTandem1). ADA 77th Scientific Sessions; 10th June; San Diego, CA: American Diabetes Association, 2017.
18. Polidori D, Sha S, Mudaliar S, Ciaraldi TP, Ghosh A, Vaccaro N et al. Canagliflozin Lowers Postprandial Glucose and Insulin by Delaying Intestinal Glucose Absorption in Addition to Increasing Urinary Glucose Excretion: Results of a randomized, placebo-controlled study. Diabetes Care 2013; 36: 2154–2161.
19. Grempler R, Thomas L, Eckhardt M, Himmelsbach F, Sauer A, Sharp DE et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab 2012; 14: 83–90.
20. Stenlof K, Cefalu WT, Kim KA, Jodar E, Alba M, Edwards R et al. Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study. Curr Med Res Opin 2014; 30: 163–175.
21. Bailey CJ, Morales Villegas EC, Woo V, Tang W, Ptaszynska A, List JF. Efficacy and safety of dapagliflozin monotherapy in people with Type 2 diabetes: a randomized double-blind placebo-controlled 102-week trial. Diabet Med 2015; 32: 531–541.
22. Roden M, Weng J, Eilbracht J, Delafont B, Kim G, Woerle HJ et al. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol 2013; 1: 208–219.
23. Tamez HE, Tamez AL, Garza LA, Hernandez MI, Polanco AC. Dapagliflozin as an adjunct therapy to insulin in the treatment of patients with type 1 diabetes mellitus. J Diabetes Metab Disord 2015; 14: 78.
24. Pieber TR, Famulla S, Eilbracht J, Cescutti J, Soleymanlou N, Johansen OE et al. Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1). Diabetes Obes Metab 2015; 17: 928–935.
25. Henry RR, Thakkar P, Tong C, Polidori D, Alba M. Efficacy and Safety of Canagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, as Add-On to Insulin in Patients With Type 1 Diabetes. Diabetes Care 2015; 38: 2258–2265.
26. Min SH, Yoon JH, Hahn S, Cho YM. Comparison between SGLT2 Inhibitors and DPP4 Inhibitors Added to Insulin Therapy in Type 2 Diabetes: A Systematic Review with Indirect Comparison Meta-analysis. Diabetes Metab Res Rev 2016; 33: https://doi.org/10.1002/dmrr.2818.
27. Tang H, Cui W, Li D, Wang T, Zhang J, Zhai S et al. Sodium-glucose co-transporter 2 inhibitors in addition to insulin therapy for management of type 2 diabetes mellitus: A meta-analysis of randomized controlled trials. Diabetes Obes Metab 2017; 19: 142–147.
28. Wang Y, Hu X, Liu X, Wang Z. An overview of the effect of sodium glucose cotransporter 2 inhibitor monotherapy on glycemic and other clinical laboratory parameters in type 2 diabetes patients. Ther Clin Risk Manag 2016; 12: 1113–1131.
29. Zaccardi F, Webb DR, Htike ZZ, Youssef D, Khunti K, Davies MJ. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis. Diabetes Obes Metab 2016; 18: 783–794.
30. Ohgaki R, Wei L, Yamada K, Hara T, Kuriyama C, Okuda S et al. Interaction of the Sodium/Glucose Cotransporter (SGLT) 2 inhibitor Canagliflozin with SGLT1 and SGLT2. J Pharmacol Exp Ther 2016; 358: 94–102.
31. Tang H, Cui W, Li D, Wang T, Zhang J, Zhai S et al. Sodium-glucose co-transporter 2 inhibitors in addition to insulin therapy for management of type 2 diabetes mellitus: A meta-analysis of randomized controlled trials. Diabetes Obes Metab 2017; 19: 142–147.
32. Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB. Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition. Diabetes Care 2015; 38: 1687–1693.
33. Erondu N, Desai M, Ways K, Meininger G. Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program. Diabetes Care 2015; 38: 1680–1686.
34. Peters AL, Henry RR, Thakkar P, Tong C, Alba M. Diabetic Ketoacidosis With Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, in Patients With Type 1 Diabetes. Diabetes Care 2016; 39: 532–538.
35. ® (canagliflozin) prescribing information. Titusville, NJ: Janssen Pharmaceuticals, Inc. Available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/204042s022lbl.pdf. Last accessed 14 November 2017.
36. ® (empagliflozin) prescribing information. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/204629s008lbl.pdf. Accessed 21 September 2017.
37. ® (dapagliflozin) prescribing information. Wilmington, DE: AstraZeneca Pharmaceuticals LP. Available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202293s010lbl.pdf. Accessed 21 September 2017.
38. Canagliflozin (Invokana, Invokamet) and Dapagliflozin (Farxiga, Xigduo XR): Drug Safety Communication - Strengthened Kidney Warnings. Silver Spring, MD: U.S. Department of Health and Human Services. Available at https://www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm506554.htm. Last accessed 20 September 2017.
39. Lapuerta P, Zambrowicz B, Strumph P, Sands A. Development of sotagliflozin, a dual sodium-dependent glucose transporter 1/2 inhibitor. Diab Vasc Dis Res 2015; 12: 101–110.
40. Product Information: Sotagliflozin. Ann Arbor, MI: Cayman Chemical. Available at http://www.caymaneurope.com/pdfs/19141.pdf. Accessed 14 November 2016.
41. Zambrowicz B, Freiman J, Brown PM, Frazier KS, Turnage A, Bronner J et al. LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clin Pharmacol Ther 2012; 92: 158–169.
42. Powell DR, Smith MG, Doree DD, Harris AL, Greer J, DaCosta CM et al. LX2761, a Sodium/Glucose Cotransporter 1 Inhibitor Restricted to the Intestine, Improves Glycemic Control in Mice. J Pharmacol Exp Ther 2017; 362: 85–97.
43. Zambrowicz B, Ogbaa I, Frazier K, Banks P, Turnage A, Freiman J et al. Effects of LX4211, a dual sodium-dependent glucose cotransporters 1 and 2 inhibitor, on postprandial glucose, insulin, glucagon-like peptide 1, and peptide tyrosine tyrosine in a dose-timing study in healthy subjects. Clin Ther 2013; 35(1162–1173): e8.
44. Devineni D, Curtin CR, Polidori D, Gutierrez MJ, Murphy J, Rusch S et al. Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus. J Clin Pharmacol 2013; 53: 601–610.
45. den Besten G, van Eunen K, Groen AK, Venema K, Reijngoud D-J, Bakker BM. The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. J Lipid Res 2013; 54: 2325–2340.
46. Hare KJ, Knop FK, Asmar M, Madsbad S, Deacon CF, Holst JJ et al. Preserved inhibitory potency of GLP-1 on glucagon secretion in type 2 diabetes mellitus. J Clin Endocrinol Metab 2009; 94: 4679–4687.
47. Batterham RL, Cohen MA, Ellis SM, Le Roux CW, Withers DJ, Frost GS et al. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 2003; 349: 941–948.
48. Rosenstock J, Cefalu WT, Lapuerta P, Zambrowicz B, Ogbaa I, Banks P et al. Greater dose-ranging effects on A1C levels than on glucosuria with LX4211, a dual inhibitor of SGLT1 and SGLT2, in patients with type 2 diabetes on metformin monotherapy. Diabetes Care 2015; 38: 431–438.
49. Baker C, Wason S, Banks P, Sawhney S, Strumph P. 70-OR: A 12-Week Dose-Ranging Study of Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes (inTandem4). ADA 77th Scientific Sessions; 10th June; San Diego, CA: American Diabetes Association; 2017.
50. Tang W, Leil TA, Johnsson E, Boulton DW, LaCreta F. Comparison of the pharmacokinetics and pharmacodynamics of dapagliflozin in patients with type 1 versus type 2 diabetes mellitus. Diabetes Obes Metab 2016; 18: 236–240.
51. Cariou B, Charbonnel B. Sotagliflozin as a potential treatment for type 2 diabetes mellitus. Expert Opin Investig Drugs 2015; 24: 1647–1656.
52. Zambrowicz B, Lapuerta P, Strumph P, Banks P, Wilson A, Ogbaa I et al. LX4211 therapy reduces postprandial glucose levels in patients with type 2 diabetes mellitus and renal impairment despite low urinary glucose excretion. Clin Ther 2015; 37(71–82): e12.
53. Macha S, Mattheus M, Halabi A, Pinnetti S, Woerle HJ, Broedl UC. Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment. Diabetes Obes Metab 2014; 16: 215–222.
54. Devineni D, Curtin CR, Marbury TC, Smith W, Vaccaro N, Wexler D et al. Effect of Hepatic or Renal Impairment on the Pharmacokinetics of Canagliflozin, a Sodium Glucose Co-transporter 2 Inhibitor. Clin Ther 2015; 37(610–628): e4.
55. Kohan DE, Fioretto P, Tang W, List JF. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int 2014; 85: 962–971.
56. Kashiwagi A, Takahashi H, Ishikawa H, Yoshida S, Kazuta K, Utsuno A et al. A randomized, double-blind, placebo-controlled study on long-term efficacy and safety of ipragliflozin treatment in patients with type 2 diabetes mellitus and renal impairment: results of the long-term ASP1941 safety evaluation in patients with type 2 diabetes with renal impairment (LANTERN) study. Diabetes Obes Metab 2015; 17: 152–160.
57. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M et al. Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach. Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364–1379.
58. Zambrowicz B, Ding ZM, Ogbaa I, Frazier K, Banks P, Turnage A et al. Effects of LX4211, a dual SGLT1/SGLT2 inhibitor, plus sitagliptin on postprandial active GLP-1 and glycemic control in type 2 diabetes. Clin Ther 2013; 35(273–285): e7.
59. Sands AT, Zambrowicz BP, Rosenstock J, Lapuerta P, Bode BW, Garg SK et al. Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in type 1 diabetes. Diabetes Care 2015; 38: 1181–1188.
60. Bode BW, Banks P, Sawhney S, Strumph P. 147-LB — 2017: 12-Week Efficacy and Safety of Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Young Adults with Poorly Controlled Type 1 Diabetes (JDRF Study). ADA 77th Scientific Sessions; 11th June; San Diego, CA: American Diabetes Association, 2017.
61. Wu JH, Foote C, Blomster J, Toyama T, Perkovic V, Sundstrom J et al. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 2016; 4: 411–419.
62. Watts NB, Bilezikian JP, Usiskin K, Edwards R, Desai M, Law G et al. Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus. J Clin Endocrinol Metab 2016; 101: 157–166.
63. Lexicon pharmaceuticals announces opt-in decision for U.S. co-promotion of sotagliflozin with Sanofi in type 1 diabetes. Texas: Lexicon Pharmaceuticals, Inc. Available at http://www.lexpharma.com/media-center/news/642-lexicon-pharmaceuticals-announces-opt-in-decision-for-u-s-co-promotion-of-sotagliflozin-with-sanofi-in-type-1-diabetes. Last accessed 20 September 2017.
64. Heise T, Seman L, Macha S, Jones P, Marquart A, Pinnetti S et al. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of Empagliflozin in Patients with Type 2 Diabetes Mellitus. Diabetes Ther 2013; 4: 331–345.
65. Parkinson J, Tang W, Johansson CC, Boulton DW, Hamrén B. Comparison of the exposure–response relationship of dapagliflozin in adult and paediatric patients with type 2 diabetes mellitus. Diabetes Obes Metab 2016; 18: 685–692.
66. Kasichayanula S, Liu X, Lacreta F, Griffen SC, Boulton DW. Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet 2014; 53: 17–27.